<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345033</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH072635</org_study_id>
    <secondary_id>R01MH072635</secondary_id>
    <secondary_id>DSIR 83-ATAP</secondary_id>
    <nct_id>NCT00345033</nct_id>
  </id_info>
  <brief_title>Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia</brief_title>
  <official_title>Aripiprazole for Clozapine Associated Medical Morbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of combination treatment with aripiprazole and clozapine
      on insulin resistance, blood fat levels, and weight gain in people diagnosed with
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a severely disabling brain disorder. People with schizophrenia often
      experience hallucinations and delusions, as well as overall difficulty with everyday
      functioning. Although the medications available to treat the disorder are generally
      effective, many cause undesirable side effects. Clozapine, for example, is a strong
      tranquilizer that functions like an antipsychotic medication. It has been shown to be
      effective in reducing the symptoms of schizophrenia, but can bring about serious side
      effects, including heart failure, weight gain, and diabetes. Aripiprazole, an atypical
      antipsychotic medication, has been shown to have fewer side effects than older antipsychotic
      drugs. The addition of aripiprazole to a clozapine treatment regimen may reduce the negative
      side effects of clozapine. This study will evaluate the effects of combination treatment with
      aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people
      with schizophrenia.

      Individuals interested in participating in this 8-week, double-blind study will first attend
      a screening session at the study site. Medical and psychiatric evaluations will be completed,
      blood samples will be taken, and an EKG will be performed. Eligible participants will undergo
      baseline assessments and then be randomly assigned to receive either aripiprazole or placebo
      in addition to their prescribed dose of clozapine. Participants will take one 15-mg capsule
      of their assigned medication once a day for 8 weeks. Study visits will occur biweekly for the
      first 8 weeks, followed by one final follow-up visit at Week 12. At each study visit,
      medication will be distributed, and the following criteria will be assessed: vital signs;
      weight; complete blood count; medication side effects; and extrapyramidal symptoms (EPS),
      which are potential neurological side effects of antipsychotic medications and may include
      involuntary movements, tremors, and rigidity. The Week 8 visit will include an EKG, and
      assessments of the following criteria: vital signs; medication side effects; treatment
      efficacy; blood counts; weight and height; and waist and hip circumference. At baseline and
      Week 8, participants will also undergo a frequently sampled intravenous glucose tolerance
      test (FSIVGTT). This involves intravenous infusion of glucose followed by frequent blood
      sampling to measure insulin and glucose concentrations. During the 4 days prior to each
      FSIVGTT, participants will record their food intake and wear an activity monitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
    <description>A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
    <description>A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
    <description>A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glucose Metabolism</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
    <description>A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin Resistance</measure>
    <time_frame>Measured at Baseline and Week 8</time_frame>
    <description>A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take aripiprazole 15mg/day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>15-mg dose once a day for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet placebo dose once a day for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia (any subtype) or schizoaffective disorder (any subtype)

          -  Treatment with clozapine for at least 1 year

          -  Stable dose of clozapine for at least 1 month

          -  Well established compliance with outpatient medications

          -  Female participants of non-childbearing potential or of childbearing potential and
             willing to practice appropriate birth control methods (complete abstinence from sexual
             intercourse, female sterilization, sterilization of male partner, implants of
             levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or
             double barrier methods of contraception using spermicide with either a condom or
             diaphragm) during the study

        Exclusion Criteria:

          -  Current substance abuse

          -  Psychiatrically unstable

          -  Significant medical illness, including severe cardiovascular, hepatic, or renal
             disease

          -  History of immunosuppression

          -  Current or recent radiation or chemotherapy treatment for cancer

          -  Chronic use of steroids

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C. Henderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Schizophrenia Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG; Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003 Apr;166(4):391-9. Epub 2003 Feb 28.</citation>
    <PMID>12610718</PMID>
  </reference>
  <reference>
    <citation>Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999 Sep-Oct;40(5):438-43.</citation>
    <PMID>10479950</PMID>
  </reference>
  <reference>
    <citation>Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999 Jun;84(6):1932-7.</citation>
    <PMID>10372689</PMID>
  </reference>
  <reference>
    <citation>Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000 Jun;157(6):975-81.</citation>
    <PMID>10831479</PMID>
  </reference>
  <reference>
    <citation>Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 1;61(2-3):123-36.</citation>
    <PMID>12729864</PMID>
  </reference>
  <reference>
    <citation>Visser M, Fuerst T, Lang T, Salamone L, Harris TB. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study--Dual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol (1985). 1999 Oct;87(4):1513-20.</citation>
    <PMID>10517786</PMID>
  </reference>
  <reference>
    <citation>Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002 Oct;63(10):856-65.</citation>
    <PMID>12416594</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2012</results_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David C. Henderson</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Glucose Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Freedom Trail Clinic at the Erich Lindemann Mental Health Center and were studied at the General Clinical Research Center (GCRC) at the Massachusetts General Hospital (MGH), Boston and the Freedom Trail Clinic.</recruitment_details>
      <pre_assignment_details>After providing written informed consent, subjects underwent a diagnostic evaluation by a research psychiatrist using the Structured Clinical Interview for DSM-IV (SCID). All subjects were screened and enrolled based on eligibility criteria. Baseline study assessments were completed prior to intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Participants will take aripiprazole for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take placebo for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>Participants will take aripiprazole for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take placebo for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="8.2"/>
                    <measurement group_id="B2" value="44.2" spread="8.9"/>
                    <measurement group_id="B3" value="44.25" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Cholesterol</title>
        <description>A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8.</description>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N = 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8.</description>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N = 30).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="33.3"/>
                    <measurement group_id="O2" value="5.6" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in total cholesterol is over 99%.</non_inferiority_desc>
            <p_value>0.125</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight</title>
        <description>A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8.</description>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8.</description>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.3"/>
                    <measurement group_id="O2" value="0.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in weight will be over 99%.</non_inferiority_desc>
            <p_value>0.109</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8.</description>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8.</description>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.79"/>
                    <measurement group_id="O2" value="0.03" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in Body Mass Index (BMI) will be over 99%.</non_inferiority_desc>
            <p_value>0.229</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose Metabolism</title>
        <description>A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8.</description>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Metabolism</title>
          <description>A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8.</description>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30).</population>
          <units>min^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.006"/>
                    <measurement group_id="O2" value="-0.005" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in glucose metabolism to be 90%.</non_inferiority_desc>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Triglycerides</title>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30)</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="75.1"/>
                    <measurement group_id="O2" value="-7.3" spread="100.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in triglycerides will be 81%.</non_inferiority_desc>
            <p_value>0.982</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Resistance</title>
        <description>A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8.</description>
        <time_frame>Measured at Baseline and Week 8</time_frame>
        <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30)</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will take aripiprazole for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take placebo for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance</title>
          <description>A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8.</description>
          <population>The number of participants for analysis (intent to treat) were those that completed the study (N=30)</population>
          <units>HOMA score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.8"/>
                    <measurement group_id="O2" value="0.65" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A priori power calculation determined the power to detect a change in Insulin Resistance will be 90%.</non_inferiority_desc>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Participants will take aripiprazole for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take placebo for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye irritation/swelling</sub_title>
                <description>Subject visited Mass Eye and Ear with eye swelling and irritation. He was given Visine Tears after which the swelling and irritation resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomach pain</sub_title>
                <description>Subject called ambulance for stomach pain. She was given Maalox at the ER, which resolved the symptom, and she was discharged.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness during IVGTT procedure</sub_title>
                <description>Subject experienced dizziness and hunger during IVGTT procedure. He was given orange juice and food, and the symptoms had resolved by the time he left the hospital. Coordinator contacted subject later that afternoon who reported feeling fine.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric decompensation</sub_title>
                <description>Subject stayed at McLean Hospital for psychiatric evaluation over 1 night. His medications were not changed. He was seen by his psychiatrist 6 days later who confirmed that subject was doing well. Subject was admitted prior to any study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>psychiatric decompensation</sub_title>
                <description>Subject was hospitalized at BI after worsening psychiatric symptoms. It was discovered that subject was taking a lesser dosage than proscribed of his antipsychotic. Subject's dosage was adjusted and he was released.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>psychiatric decompensation</sub_title>
                <description>Subject stopped taking all of his medications including study medication, and was hospitalized after worsening psychiatric symptoms. Subject was terminated from the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <description>Subject experienced asthma attack. Subject has a history of asthma. Subject was given two nebulizer treatments at urgent care, which resolved the symptom, and she was released the same night. Subject was proscribed Adviar.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study include the relatively small sample size, short intervention period (8 weeks) and the lack of generalizability of our findings to patients with schizophrenia treated by antipsychotic agents other than clozapine.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David C. Henderson</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>(617) 912-7800</phone>
      <email>dchenderson@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

